Meeting
2022 ASCO Genitourinary Cancers Symposium
Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study.
Authors
Omar Alhalabi
The University of Texas MD Anderson Cancer Center, Houston, TX
Omar Alhalabi , Jonathan Thouvenin , Sylvie Negrier , Yann-Alexandre Vano , Luca Campedel Jr., Elshad Hasanov , Ziad Bakouny , Andrew Warren Hahn , Mehmet Asim Bilen , Toni K. Choueiri , Srinivas Raghavan Viswanathan , Kanishka Sircar , Laurence Albiges , Gabriel Malouf , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 343)
DOI
10.1200/JCO.2022.40.6_suppl.343
Abstract #
343
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre